Shimla Online

Acute Ocular Pain Market Insight, Epidemiology And Market Forecast -2030

 Breaking News
  • No posts were found

Acute Ocular Pain Market Insight, Epidemiology And Market Forecast -2030

August 23
12:32 2021
Acute Ocular Pain Market Insight, Epidemiology And Market Forecast -2030
DelveInsight Business Research LLP
DelveInsight’s ‘Acute Ocular Pain Market’ report deliver an in-depth understanding of the AOP, historical and forecasted epidemiology as well as the AOP market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Acute Ocular Pain Market

The AOP market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM AOP market size from 2018–2030. The Report also covers current AOP treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Acute Ocular Pain Market Outlook

Eye pain is a myriad of symptoms ranging from a sharp pain in the eye to mild discomfort or itching in the eyes. As the spectrum of symptom presentation varies with eye pain, the cause of these pains may vary from very simple refractive errors to potentially sight-threatening disorders like glaucoma and uveitis. A feeling of discomfort or pain in the eye can be caused by a problem in the eye itself. It can also be caused by a problem involving any structures around the eye or referred pain from tissues with similar innervation as ocular tissues. Most ophthalmologic conditions producing ocular pains are associated with obvious ocular symptoms and signs like red-eye, photophobia, vision loss, or diplopia. Sometimes it poses a challenge to physicians when the pain is associated with a quiet eye or “white eye.”

Pain associated with surgery, injury, infection, or inflammation at the front of the eye is typically treated with a topical steroid, topical NSAID, systemic NSAID, lubricant ointment, gel or drops, bandage contact lens, or a few doses of oral opiate or topical anesthetic.

Recently various drugs such as Dextenza, Inveltys, BromSite, and Lotemax have been approved to treat ocular inflammation and pain following ophthalmic surgery and cataract surgery. Dextenza is the first FDA-approved intracanalicular insert, a novel route of administration that delivers the drug to the eye’s surface without the need for eye drops. The drug is a preservative-free, resorbable hydrogel insert that delivers 0.4 mg of dexamethasone to treat postsurgical ocular inflammation and pain for up to 30 days with a single administration.

Key Findings

  • The market size of Acute Ocular Pain in the 7MM was estimated to be USD 276.02 million in 2020, and it is estimated to grow at a Compound Annual Growth Rate (CAGR) of 8.93% for the study period (2018–2030).
  • According to the estimates, the highest market size of Acute Ocular Pain (AOP) was found in the United States, followed by Germany in the year 2020.
  • The market size of AOP in the EU5 was estimated to be USD 89.18 million in 2020, and it is estimated to grow at a Compound Annual Growth Rate (CAGR) of 7.80% for the study period (2018–2030).
  • Among the EU5 countries, Germany had the highest market size of AOP with USD 22.13 million in 2020, while Spain had the lowest market size for AOP with USD 13.06 million in 2020.
  • Dextenza, Inveltys, and Lotemax SM—already approved in the US market—are expected to enter the European and Japan market in 2023, 2024, and 2024, respectively.

“Currently NSAIDs, Steroids, and others (Antibiotics) are used to manage acute ocular pain. These therapies are further classified into monotherapies and combination therapies. In combination therapies, the combination of Antibiotics + Steroids, NSAIDS + Antibiotics + Steroids, and others (Antibiotics + NSAIDs; Steroids + NSAIDs) are prescribed by the physicians as off-label therapies to manage ocular pain.

Dextenza, Inveltys, and Lotemax SM are the recently approved drugs indicated for post-operative pain management of cataract surgery. All these three therapies were launched in the US market in 2019. The other upcoming therapies that are being investigated for pain management in the case of Cataract surgeries and Dry Eye Disease (DED) include, APP13007, Reproxalap, and Tivanisiran (SYL1001). Reproxalap and Tivanisiran (SYL1001) are the only upcoming therapies that will be targeting the DED patient pool, and hence will be competing with each other. In their clinical results, it was observed that the drugs were successfully able to manage pain in the case of DED.

Reproxalap is estimated to capture the largest market among the upcoming therapies because it will be targeting the overall patient pool of DED.”

The United States Market Outlook

This section provides the total AOP market size and market size by therapies in the United States.

EU-5 Market Outlook

The total AOP market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total AOP market size and market size by therapies in Japan are provided.

Request for sample pages @ Acute Ocular Pain Market Size 

Table of contents

1. Key Insights

2. Report Introduction

3. Acute Ocular Pain (AOP) Market Overview at a Glance

3.1. Market Share (%) Distribution of Acute Ocular Pain (AOP) in 2018

3.2. Market Share (%) Distribution of Acute Ocular Pain (AOP) in 2030

4. Executive Summary of Acute Ocular Pain (AOP)

5. Acute Ocular Pain (AOP) Market: Future Perspective

6. Disease Background and Overview

6.1. Introduction

6.2. Eye: Components and Anatomy

6.3. Causes

6.3.1. Ocular trauma

6.3.2. Conjunctival or corneal foreign body

6.3.3. Recurrent corneal erosions (RCE)

6.3.4. Dry eyes

6.3.5. Microbial keratitis

6.3.6. Glaucoma

6.3.7. Episcleritis

6.3.8. Scleritis

6.3.9. Uveitis

6.3.10. Optic neuropathies

6.3.11. Eye pain in cranial nerve palsies

6.3.12.. Eye pain in ocular asthenopia

6.3.13. Eye pain in migraine

6.3.14. Eyelid, orbit, and ocular adnexa

6.3.15. Ocular surface, conjunctiva, and cornea

6.3.16. Retinal diseases

6.4. Diagnosis

6.4.1. History

6.4.2. Physical examination

6.4.3. Testing

6.5. Differential Diagnosis and Management

6.6. Treatment and Management

6.6.1. Local treatment

6.6.1.1. Topical Ophthalmic NSAIDs

6.6.1.2. Ophthalmic Corticosteroids

6.6.1.3. Cholinergic Antagonists

6.6.1.4. Topical Anesthetics

6.6.2. Allergy eye drops

6.6.3. Surgery

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. Epidemiology Methodology

7.3. Total Cases of Several Eye Disorders in the 7MM

7.4. Total Cases of Acute Ocular Pain (AOP) in the 7MM

7.5. Epidemiology of Acute Ocular Pain (AOP)

7.6. The United States

7.6.1. Number of Cases of Several Eye disorders in the United States

7.6.2. Number of Cases of Acute Ocular Pain in Major Eye Disorders in the United States

7.7. EU5

7.7.1. Germany

7.7.1.1. Number of Cases of Several Eye Disorders in Germany

7.7.1.2. Number of Cases of Acute Ocular Pain in Major Eye Disorders in Germany

7.7.2. France

7.7.2.1. Number of Cases of Several Eye Disorders in France

7.7.2.2. Number of Cases of Acute Ocular Pain in Major Eye Disorders in France

7.7.3. Italy

7.7.3.1. Number of Cases of Several Eye Disorders in Italy

7.7.3.2. Number of Cases of Acute Ocular Pain in Major Eye Disorders in Italy

7.7.4. Spain

7.7.4.1. Number of Cases of Several Eye Disorders in Spain

7.7.4.2. Number of Cases of Acute Ocular Pain in Major Eye Disorders in Spain

7.7.5. United Kingdom

7.7.5.1. Number of Cases of Eye Disorders in the UK

7.7.5.2. Number of Cases of Acute Ocular Pain in Major Eye Disorders in the UK

7.8. Japan

7.8.1. Number of Cases of Several Eye Disorders in Japan

7.8.2. Number of Cases of Acute Ocular Pain in Major Eye Disorders in Japan

8. Organizations contributing towards Acute Ocular Pain (AOP)

9. Patient Journey

10. Case Reports

11. Marketed Products

11.1. Key Cross

11.2. Dextenza (dexamethasone ophthalmic insert): Ocular Therapeutix

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Clinical Development

11.2.4. Clinical Trials Information

11.2.5. Safety and Efficacy

11.2.6. Product Profile

11.3. Inveltys (loteprednol etabonate ophthalmic suspension/KPI-121): Kala Pharmaceuticals

11.3.1. Product Description

11.3.2. Regulatory Milestones

11.3.3. Clinical Development

11.3.4. Clinical Trials Information

11.3.5. Safety and Efficacy

11.3.6. Product Profile

11.4. BromSite (bromfenac ophthalmic solution): Sun Pharmaceutical

11.4.1. Product Description

11.4.2. Regulatory Milestones

11.4.3. Safety and Efficacy

11.4.4. Product Profile

11.5. Lotemax SM (loteprednol etabonate ophthalmic gel): Bausch & Lomb

11.5.1. Product Description

11.5.2. Regulatory Milestones

11.5.3. Safety and Efficacy

11.5.4. Product Profile

11.6. Prolensa (bromfenac ophthalmic solution) 0.07%: Bausch & Lomb

11.6.1. Product Description

11.6.2. Regulatory Milestones

11.6.3. Clinical Development

11.6.4. Clinical Trials Information

11.6.5. Safety and Efficacy

11.6.6. Product Profile

12. Emerging Therapies

12.1. Key Cross

12.2. APP13007: Formosa Pharmaceuticals

12.2.1. Drug Description

12.2.2. Regulatory Milestones

12.2.3. Clinical Development

12.2.4. Clinical Trials Information

12.2.5. Safety and Efficacy

12.2.6. Product Profile

12.3. Reproxalap: Aldeyra Therapeutics

12.3.1. Drug Description

12.3.2. Regulatory Milestones

12.3.3. Clinical Development

12.3.4. Clinical Trials Information

12.3.5. Safety and Efficacy

12.3.6. Product Profile

12.4. Tivanisiran (SYL1001): Sylentis

12.4.1 Drug Description

12.4.2. Regulatory Milestones

12.4.3. Clinical Development

12.4.4. Clinical Trials Information

12.4.5. Safety and Efficacy

12.4.6. Product Profile

13. Acute Ocular Pain (AOP): Seven Major Market Analysis

13.1. Key Findings

13.2. Market Methodology

13.3. Market Size of Acute Ocular Pain (AOP) in the 7MM

13.4. Market Size of Acute Ocular Pain (AOP) by Therapies in the 7MM

13.5. Market Outlook

13.6. Attribute Analysis

13.7. Key Market Forecast Assumptions

13.8.United States Market Size

13.8.1. Total Market Size of Acute Ocular Pain (AOP) in the United States

13.8.2. Market Size of Acute Ocular Pain (AOP) by Therapies in the United States

13.9. EU-5 Market Size

13.9.1. Germany

13.9.1.1. Total Market size of Acute Ocular Pain (AOP) in Germany

13.9.1.2. Market Size of Acute Ocular Pain (AOP) by Therapies in Germany

13.9.2. France

13.9.2.1. Total Market size of Acute Ocular Pain (AOP) in France

13.9.2.2. Market Size of Acute Ocular Pain (AOP) by Therapies in France

13.9.3. Italy

13.9.3.1. Total Market size of Acute Ocular Pain (AOP) in Italy

13.9.3.2. Market Size of Acute Ocular Pain (AOP) by Therapies in Italy

13.9.4. Spain

13.9.4.1. Total Market size of Acute Ocular Pain (AOP) in Spain

13.9.4.2. Market Size of Acute Ocular Pain (AOP) by Therapies in Spain

13.9.5. United Kingdom

13.9.5.1.Total Market size of Acute Ocular Pain (AOP) in the United Kingdom

13.9.5.2. Market Size of Acute Ocular Pain (AOP) by Therapies in the United Kingdom

13.10. Japan

13.10.1. Total Market size of Acute Ocular Pain (AOP) in Japan

13.10.2. Market Size of Acute Ocular Pain (AOP) by Therapies in Japan

14. KOL Views

15. Market Drivers

16. Market Barriers

17. SWOT Analysis

18. Unmet Needs

19. Appendix

19.1. Bibliography

19.2. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Related Articles